These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The experience and effectiveness of the Nova Scotia Rh program, 1964-84. Baskett TF; Parsons ML; Peddle LJ CMAJ; 1986 Jun; 134(11):1259-61. PubMed ID: 3011235 [TBL] [Abstract][Full Text] [Related]
6. Serum sickness due to Rh(anti-D) immunoglobulin. Jones BF; Trevillian PR; Nanra RS Aust N Z J Obstet Gynaecol; 1984 Feb; 24(1):49-50. PubMed ID: 6331369 [TBL] [Abstract][Full Text] [Related]
7. Utilization of Rh prophylaxis. Berger GS; Keith L Clin Obstet Gynecol; 1982 Jun; 25(2):267-75. PubMed ID: 6179676 [TBL] [Abstract][Full Text] [Related]
8. Rh hemolytic disease. Epidemiologic surveillance in the United States, 1968 to 1975. Wysowski DK; Flynt JW; Goldberg MF; Connell FA JAMA; 1979 Sep; 242(13):1376-9. PubMed ID: 113567 [TBL] [Abstract][Full Text] [Related]
9. Prevention of Rh hemolytic disease--ten years' clinical experience with Rh immune globulin. Freda VJ; Gorman JG; Pollack W; Bowe E N Engl J Med; 1975 May; 292(19):1014-6. PubMed ID: 804134 [TBL] [Abstract][Full Text] [Related]
10. Rh immune globulin after genetic amniocentesis: impact on pregnancy outcome. Crane JP; Rohland B; Larson D Am J Med Genet; 1984 Dec; 19(4):763-8. PubMed ID: 6097129 [TBL] [Abstract][Full Text] [Related]
12. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Rh hemolytic disease of the newborn, United States, 1960-1979. Adams MM; Gustafson J Prog Clin Biol Res; 1981; 70():213-7. PubMed ID: 6273934 [No Abstract] [Full Text] [Related]
14. Rh negative status and isoimmunization update: a case-based approach to care. Harrod KS; Hanson L; VandeVusse L; Heywood P J Perinat Neonatal Nurs; 2003; 17(3):166-78; quiz 179-80. PubMed ID: 12959478 [TBL] [Abstract][Full Text] [Related]
15. Efforts should be made to eradicate Rh hemolytic disease of the fetus and newborn. Caiola G Obstet Gynecol Surv; 1984 Jan; 39(1):55-7. PubMed ID: 6320075 [No Abstract] [Full Text] [Related]
16. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? Bowman JM Am J Obstet Gynecol; 1985 Feb; 151(3):289-94. PubMed ID: 2982267 [TBL] [Abstract][Full Text] [Related]
17. Costs and benefits of non-invasive fetal RhD determination. Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024 [TBL] [Abstract][Full Text] [Related]
18. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Chilcott J; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C; Tappenden P Health Technol Assess; 2003; 7(4):iii-62. PubMed ID: 12633527 [No Abstract] [Full Text] [Related]
19. [Evaluation of the Center for Rh-negative Mothers. Hospital Paula Jaraquemada (3 years)]. Krug A; Bianchi R; Pérez N; Ilabaca G; Farías S; Rojas E Rev Chil Obstet Ginecol; 1981; 46(4):206-14. PubMed ID: 6099901 [No Abstract] [Full Text] [Related]
20. Rh disease: how near the end? Freda VJ; Pollack W; Gorman JG Hosp Pract; 1978 Jun; 13(6):61-9. PubMed ID: 99361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]